Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas

Enrique Lerma, Lluis Catasus, Alberto Gallardo, Gloria Peiro, Carmen Alonso, Ignacio Aranda, Agusti Barnadas, Jaime Prat

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)


PIK3CA mutations at 9 and 20 exons were studied in a series of 56 selected aggressive breast carcinomas (BC): 27 with Her-2 over-expression and negativity for estrogen receptors (ER) and progesterone receptors (PR), and 29 "triple negative" BC (negative for ER, PR and Her-2). Also, immunohistochemical studies of p53, ki-67, Her-1 (EGFR), pIGF-1R, PTEN, p110α, and pAkt were performed. Six mutations in exon 20 PIK3CA were identified among the 27 Her-2 positive BC, whereas only one exon 9 PIK3CA mutation was detected in a triple negative tumor (p=0.035). Furthermore, PIK3CA mutations were associated with p110α over-expression (p=0.001). Overall survival was shorter in cases with PIK3CA mutations (p=0.015 in all series; and p=0.041 for Her-2+ tumors), although multivariate analyses did not show statistical differences. No statistical significance was related with disease-free survival. Exon 20 PIK3CA mutations are relatively frequent in Her-2+ tumors and shorten survival, whereas neither exons 9 and 20 mutations seem related with "triple negative" breast carcinomas. © 2008 Springer-Verlag.
Original languageEnglish
Pages (from-to)133-139
JournalVirchows Archiv
Issue number2
Publication statusPublished - 1 Aug 2008


  • Breast carcinoma
  • Her2-neu
  • p110
  • PIK3CA mutations

Fingerprint Dive into the research topics of 'Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas'. Together they form a unique fingerprint.

Cite this